AstraZeneca seals a $50 billion deal with Washington to lower its US prices

Aligning with International Prices in Exchange for Tax Incentives

During a press conference held at the White House on October 10, 2025, Donald Trump outlined the details of the agreement reached with AstraZeneca. The pharmaceutical company has committed to applying the « most favored nation » pricing for the Medicaid program, thereby aligning its US prices with the lowest rates offered in developed countries. This measure is expected to allow Medicaid beneficiaries, the health insurance program for low-income households, to access treatments at significantly reduced costs.

Additionally, the British group has agreed to offer discounts of up to 80% off list prices for direct sales to patients with chronic illnesses, according to the company's official statement. These medications will be distributed through TrumpRx, a government platform enabling direct purchases from pharmaceutical companies, which is set to launch in early 2026.

In exchange for these pricing commitments, the US Department of Commerce has granted AstraZeneca a three-year exemption from tariffs. This waiver is a significant relief for the company, as the Trump administration had been threatening a 100% tariff on imported patented drugs. Pascal Soriot, CEO of AstraZeneca, expressed particular gratitude for this exemption during the White House ceremony, noting it will allow the company to gradually repatriate its production to US soil.

A $50 Billion Commitment to Reshore American Manufacturing

The tariff agreement is part of a large-scale investment strategy announced by AstraZeneca in July 2025. The pharmaceutical group plans to invest $50 billion in the United States by 2030 in drug production and research and development. The cornerstone of this plan is the construction of a $4.5 billion facility in Albemarle County, Virginia, with work that began on October 9, 2025. This site, set to be the largest ever built by AstraZeneca, will include two separate facilities.

The first will focus on manufacturing small molecules aimed at treating chronic diseases, including medications for obesity, hypertension, and cholesterol. The second will be dedicated to producing antibody-drug conjugates for cancer therapies. The plant is expected to create 600 highly skilled direct jobs, including engineers, scientists, and production technicians, as well as 3,000 indirect jobs in the region. The choice of Virginia is no coincidence.

Pascal Soriot has developed a close relationship with Republican Governor Glenn Youngkin, an ally of Donald Trump, according to three sources close to the negotiations interviewed by Reuters. The agreement was reached in just 33 days between the first conversation and the signing of the partnership. AstraZeneca currently employs over 18,000 people in the United States and has 19 production, research, and commercial sites. The group aims to increase the US market's share of its global revenue from 42% currently to 50% by 2030, as part of an annual revenue target of $80 billion.

Feared Impacts on European Prices

While the agreement between AstraZeneca and Washington appears favorable for American patients, it raises significant concerns in Europe regarding its potential impact on drug prices. The most-favored-nation pricing policy, which requires pharmaceutical companies to align their US prices with the lowest rates available in developed countries, might prompt these companies to raise prices in Europe to offset the reduction in their profit margins across the Atlantic. Alexander Natz, Secretary General of Eucope, a European pharmaceutical industry trade association, warned that while this pricing strategy may seem like a national measure, it could actually have global repercussions. In France, where drugs cost on average four times less than in the United States according to Thierry Hulot, president of Leem, the French pharmaceutical industry association, there is particular concern about the risk of price increases. A 2024 study by the Rand Corporation confirms this disparity, indicating that Americans pay 2.78 times more for their prescription drugs than residents of the 33 OECD countries. For brand-name drugs, this ratio rises to 4.22 times. However, some experts downplay the real impact of these agreements on consumers. Sean Sullivan, a health economist at the University of Washington, described the TrumpRx direct sales platform as merely a communication tactic, noting that most American patients obtain their medications through their health insurance. Similarly, Medicaid beneficiaries already benefit from price protection, ensuring access to the lowest prices available to commercial insurers in the US, which limits the effective scope of the agreement for this group of patients.